PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 8383401-3 1993 Both lidocaine and bupivacaine inhibited the release of the inflammatory mediators leukotriene B4 (LTB4) and interleukin-1 (IL-1) evaluated by radioimmunoassay (RIA). Lidocaine 5-14 interleukin 1 alpha Homo sapiens 109-128 8383401-5 1993 In short-term (24 h) cultures of mononuclear cells the addition of lidocaine or bupivacaine reduced, in a dose-dependent manner, the level of IL-1 detected after stimulation with lipopolysaccharide (LPS). Lidocaine 67-76 interleukin 1 alpha Homo sapiens 142-146 30963625-9 2019 Lidocaine dramatically reduced the protein expression of IL-1alpha, IL-6, THF-alpha, ELAVL1, NLRP3, caspase-1, and IL-1beta in adenovirus-infected thyroid follicular epithelial cells. Lidocaine 0-9 interleukin 1 alpha Homo sapiens 57-66 35482438-5 2022 HYPOTHESIS: Treatment of articular cartilage with IL-1Ra in combination with a clinically relevant concentration of lidocaine (1%) will inhibit the catabolic effects of IL-1alpha in a manner similar to treatment with IL-1Ra alone. Lidocaine 116-125 interleukin 1 alpha Homo sapiens 169-178 35482438-11 2022 RESULTS: The combination of IL-1Ra and lidocaine, premixed at various time points and stored at room temperature or 4 C, was as effective as IL-1Ra alone at inhibiting IL-1alpha-mediated sGAG release. Lidocaine 39-48 interleukin 1 alpha Homo sapiens 168-177 35482438-13 2022 CONCLUSION: Our hypothesis was supported, and results indicated that the combination of IL-1Ra and lidocaine was as efficacious as IL-1Ra treatment alone in acutely mitigating biological cartilage injury due to IL-1alpha in an explant model. Lidocaine 99-108 interleukin 1 alpha Homo sapiens 211-220 27309886-0 2016 Effect of intravenous lidocaine combined with amitriptyline on pain intensity, clinical manifestations and the concentrations of IL-1, IL-6 and IL-8 in patients with fibromyalgia: A randomized double-blind study. Lidocaine 22-31 interleukin 1 alpha Homo sapiens 129-133